Joel Greenblatt's DGX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 130,777 shares of Quest Diagnostics Incorporated (DGX) worth $25.63 M, representing 0.08% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2015, adding 318,726 shares. Largest reduction occurred in Q4 2015, reducing 329,756 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +51,382 | Add 64.72% | 130,777 | $195.98 |
| Q4 2025 | +24,701 | Add 45.16% | 79,395 | $173.53 |
| Q3 2025 | +24,881 | Add 83.46% | 54,694 | $190.58 |
| Q2 2025 | +20,529 | Add 221.12% | 29,813 | $179.63 |
| Q1 2025 | +7,943 | Add 592.32% | 9,284 | $169.20 |
| Q4 2024 | -525 | Reduce 28.14% | 1,341 | $150.86 |
| Q3 2024 | -4,879 | Reduce 72.34% | 1,866 | $155.25 |
| Q2 2024 | -11,414 | Reduce 62.86% | 6,745 | $136.88 |
| Q1 2024 | +18,159 | New Buy | 18,159 | $133.11 |
| Q2 2023 | -1,990 | Sold Out | 0 | $0.00 |
| Q1 2023 | -21,701 | Reduce 91.60% | 1,990 | $141.48 |
| Q4 2022 | +3,073 | Add 14.90% | 23,691 | $156.44 |
| Q3 2022 | -8,304 | Reduce 28.71% | 20,618 | $122.71 |
| Q2 2022 | -3,623 | Reduce 11.13% | 28,922 | $132.98 |
| Q1 2022 | +8,782 | Add 36.96% | 32,545 | $136.86 |
| Q4 2021 | -9,983 | Reduce 29.58% | 23,763 | $173.00 |
| Q3 2021 | +15,807 | Add 88.12% | 33,746 | $145.32 |
| Q2 2021 | -8,138 | Reduce 31.21% | 17,939 | $131.95 |
| Q1 2021 | -28,059 | Reduce 51.83% | 26,077 | $128.35 |
| Q4 2020 | +43,183 | Add 394.26% | 54,136 | $119.16 |
| Q3 2020 | -1,547 | Reduce 12.38% | 10,953 | $114.49 |
| Q2 2020 | -82,470 | Reduce 86.84% | 12,500 | $113.92 |
| Q1 2020 | +1,121 | Add 1.19% | 94,970 | $80.30 |
| Q4 2019 | +4,659 | Add 5.22% | 93,849 | $106.79 |
| Q3 2019 | +14,753 | Add 19.82% | 89,190 | $107.03 |
| Q2 2019 | -47,633 | Reduce 39.02% | 74,437 | $101.80 |
| Q1 2019 | +252 | Add 0.21% | 122,070 | $89.92 |
| Q4 2018 | +63,675 | Add 109.51% | 121,818 | $83.27 |
| Q3 2018 | +55,519 | Add 2115.82% | 58,143 | $107.91 |
| Q2 2018 | -162,206 | Reduce 98.41% | 2,624 | $109.76 |
| Q1 2018 | -98,339 | Reduce 37.37% | 164,830 | $100.30 |
| Q4 2017 | +119,278 | Add 82.89% | 263,169 | $98.49 |
| Q3 2017 | +47,989 | Add 50.04% | 143,891 | $93.64 |
| Q2 2017 | -85,076 | Reduce 47.01% | 95,902 | $111.16 |
| Q1 2017 | -53,394 | Reduce 22.78% | 180,978 | $98.19 |
| Q4 2016 | -73,848 | Reduce 23.96% | 234,372 | $91.90 |
| Q3 2016 | +130,782 | Add 73.71% | 308,220 | $84.63 |
| Q2 2016 | -71,783 | Reduce 28.80% | 177,438 | $81.41 |
| Q1 2016 | -21,054 | Reduce 7.79% | 249,221 | $71.45 |
| Q4 2015 | -329,756 | Reduce 54.96% | 270,275 | $71.14 |
| Q3 2015 | +318,726 | Add 113.30% | 600,031 | $61.47 |
| Q2 2015 | +224,521 | Add 395.39% | 281,305 | $72.52 |
| Q1 2015 | -31,435 | Reduce 35.63% | 56,784 | $76.85 |
| Q4 2014 | -149,838 | Reduce 62.94% | 88,219 | $67.06 |
| Q3 2014 | +233,673 | Add 5330.13% | 238,057 | $60.68 |
| Q2 2014 | -72,028 | Reduce 94.26% | 4,384 | $58.62 |
| Q1 2014 | -202,776 | Reduce 72.63% | 76,412 | $57.92 |
| Q4 2013 | +235,126 | Add 533.63% | 279,188 | $53.54 |
| Q3 2013 | +12,868 | Add 41.25% | 44,062 | $61.80 |
| Q2 2013 | +31,194 | Add 0.00% | 31,194 | $60.62 |
Joel Greenblatt's Quest Diagnostics Incorporated Investment FAQs
Joel Greenblatt first purchased Quest Diagnostics Incorporated (DGX) in Q2 2013, acquiring 31,194 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Quest Diagnostics Incorporated (DGX) for 50 quarters since Q2 2013.
Joel Greenblatt's largest addition to Quest Diagnostics Incorporated (DGX) was in Q3 2015, adding 600,031 shares worth $36.88 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 130,777 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $25.63 M.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.08% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Quest Diagnostics Incorporated (DGX) was 600,031 shares, as reported at the end of Q3 2015.